Loading…
Biotech engineering bispecific antibodies and antibody-drug conjugates; zanidatamab targets HER2 cancers with Jazz Pharmaceuticals.
Biotech engineering bispecific antibodies and antibody-drug conjugates; zanidatamab targets HER2 cancers with Jazz Pharmaceuticals.
Has no product of its own on the market; income arrives as milestone payments and royalties when partners reach goals or sell drugs built on its technology. Jazz holds zanidatamab rights in most of the world outside Asia, where BeiGene holds them for parts of Asia-Pacific.
Moat: narrow (IP / patents, process know-how). Proprietary Azymetric bispecific-antibody platform is licensed to multiple large pharma partners.
Headquarters: Vancouver, Canada · Founded: 2003 · Employees: 264
Size Zymeworks (ZYME) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.10B, the 1760th largest of 3,117 United States companies the cockpit tracks. Shares closed at $29.63 on 6 Nov 2026.
Performance Over six months the shares gained 24.0%, against -12.0% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 69.8% over the last twelve months (peer median +0.4%); the operating margin is -419.0% (peer median 12.4%).
Valuation It trades at 12.0× forward earnings against a peer median of 19.3× (4th cheapest of 18).
Capital Return on invested capital runs 167.7 points below its cost of capital (10.8% WACC).
Short interest Short interest is 7.9% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $37.1M | $106M | $76.3M | $76.0M | $412M |
| Revenue growth | — | +39% | 0% | -82% | — |
| Gross profit | $28.1M | $95.2M | $65.1M | $58.7M | $400M |
| EBITDA | -$146M | -$81.8M | -$109M | -$121M | $143M |
| Net income | -$150M | -$81.1M | -$123M | -$119M | $124M |
| Free cash flow | -$120M | -$34.5M | -$112M | -$121M | $136M |
| Capital expenditure | $1.33M | $2.35M | $3.07M | $4.08M | $13.1M |
| Total debt | $269M | $18.3M | $18.5M | $26.7M | $28.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zymeworks ZYME | $2.10B | +24% | -70% | -419% | 12.0× | n/a |
| Genmab A/S GMAB.CO | $32.1B | +115% | +14% | 32% | 44.8× | 11.6% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 18.4× | -0.1% |
| Daiichi Sankyo 4568.T | $31.9B | +7% | +17% | 13% | 18.6× | 7.2% |
| Xencor XNCR | $2.66B | +178% | -29% | -206% | n/a | n/a |
| Sutro Biopharma STRO | n/a | -76% | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | $10.2B | -38% | +42% | -25% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZYME | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.3% | -1.0% | 3rd highest of 21 |
| 6-month return | +24.0% | -12.0% | 6th highest of 21 |
| Distance from 52-week high | -5.9% | -32.7% | 4th highest of 21 |
| Revenue growth (TTM) | -69.8% | +0.4% | lowest of 20 |
| Operating margin | -419.0% | 12.4% | lowest of 20 |
| Forward P/E | 12.0× | 19.3× | 4th cheapest of 18 |
| ROIC minus cost of capital | -167.7 pp | -2.5 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% | +15.7% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | n/a | 37.9% | +0.9% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | n/a | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 22.8× | 6.1% | +6.4% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 12.4× | 3.7% | +15.7% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 6.3× | 13.1% | +0.8% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |